Zydus Lifesciences up nearly 3% after WHO approval for typhoid vaccine

Zydus Lifesciences’ shares rose 2.81% after receiving WHO approval for its indigenously developed typhoid vaccine, ZyVac TCV, making it eligible for UN agency procurement.

Leave a Reply

Your email address will not be published. Required fields are marked *